KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsShares IssuedShares Outstanding
Ratios

NovoCure (NVCR) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for NovoCure (NVCR) over the last 11 years, with Q4 2024 value amounting to $32.3 million.

  • NovoCure's Accumulated Depreciation & Amortization rose 1555.79% to $32.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $32.3 million, marking a year-over-year increase of 1555.79%. This contributed to the annual value of $32.3 million for FY2024, which is 1555.79% up from last year.
  • Latest data reveals that NovoCure reported Accumulated Depreciation & Amortization of $32.3 million as of Q4 2024, which was up 1555.79% from $28.0 million recorded in Q4 2023.
  • In the past 5 years, NovoCure's Accumulated Depreciation & Amortization registered a high of $32.3 million during Q4 2024, and its lowest value of $18.4 million during Q4 2020.
  • Its 5-year average for Accumulated Depreciation & Amortization is $24.9 million, with a median of $23.6 million in 2022.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 2580.91% in 2020, then skyrocketed by 681.63% in 2022.
  • Quarter analysis of 5 years shows NovoCure's Accumulated Depreciation & Amortization stood at $18.4 million in 2020, then increased by 19.91% to $22.1 million in 2021, then grew by 6.82% to $23.6 million in 2022, then rose by 18.47% to $28.0 million in 2023, then grew by 15.56% to $32.3 million in 2024.
  • Its Accumulated Depreciation & Amortization was $32.3 million in Q4 2024, compared to $28.0 million in Q4 2023 and $23.6 million in Q4 2022.